Search Our Science Our technologies Antibody–drug conjugate (ADC) technology Sugar-engineered antibody (SEA) technology Seagen is an industry leader in ADC research and the use of this technology in the treatment of cancer. ADCs are designed to harness the targeting power of antibodies to deliver small molecule drugs to the tumor. This innovative approach to therapy offers meaningful efficacy while reducing side effects for patients. Read More Sharsti Sandall, Ph.D. Principal Scientist, Cancer Biology Working on antibody–drug conjugates is sort of like a cell biologist’s best dream. You get to think about all these really complicated properties of cancer cells, starting from the tumor antigen that's expressed on the cancer cells. Hear Her Story 0:36 How ADCs work Ryan Heiser, Ph.D. Principal Scientist, Immunology The dual potential to efficiently kill cancer cells directly, and to do it in a way that elicits highly focused immune recognition of tumors, holds enormous promise for combination with checkpoint inhibitors. Hear His Story 0:45 Chris Neumann, Ph.D. Principal Scientist, Chemistry What I like about working at Seagen is that solving design challenges is not the responsibility of a single group. Medical information and safety Request additional information about our medicines, or report an adverse event or product complaint. Contact Medical Information References + Patients and Caregivers Diseases We Study Real Stories Clinical Trials Support and Resources Healthcare Professionals Medical Information Clinical Data Requests Investigator-Sponsored Research Medical Education Grants Site Map Contact Us FAQs Sign up for updates This website is intended for U.S. residents only. ©2021 Seagen Inc. Privacy Policy Terms and Conditions Social Media Terms > Cookie Notification By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our Cookies Policy. Accept